Status of Injectafer lawsuits 2022
https://www.medlegal360.com/injectafer-lawsuits-trials-bring-hope/
An intravenous (IV) iron replacement therapy called
Injectafer (ferric carboxymaltose) is used to treat iron deficiency anaemia
(IDA). Once within the body, it was made to release iron gradually, potentially
lowering the possibility of side effects and delivering more iron in only two
doses. The interval between the two doses should be seven days. Itching,
rashes, allergic skin reactions, wheezing, shock, low blood pressure, loss of
consciousness, and even death among users are all possible side effects of
injectafer.
Vifor Pharmaceuticals is a manufacturer of Injectafer in
Switzerland. In some nations, it is offered under the brand name Ferinject.
American Regent, formerly known as Luitpold Pharmaceuticals, distributes it in
the US. Due to manufacturing issues, the FDA also rejected the application that
was submitted in 2011. On July 25, 2013, the FDA only accepted the NDA when
Luitpold resubmitted it.
Injectafer is accused of inducing hypophosphatemia, which is
the major claim in the litigation. It is a medical disorder that causes the
bones and muscles to weaken because of low phosphate levels in the blood. Many
of the 5000 or so adverse event reports claimed that Injectafer
was to blame for serious HPP, respiratory failure, cardiovascular problems, and
other side effects.
The negative effects of the medicine were not fully
disclosed to the general public or the medical community. To caution the
public, they did not include any warnings on their labels. Only after receiving
a notice from the FDA to change their warning label in 2020 did the
manufacturer add a note to their label referring to "symptomatic
Hypophosphatemia". It was a very late measure because many patients had
already suffered enough harm in the seven years prior.
Before US District Judge Wendy Beetlestone, more than 100 Injectafer
lawsuits have been consolidated, and she is getting ready to schedule early
trial dates in a select number of "bellwether" cases. In a
preliminary scheduling order, Judge Beetlestone declared on September 15 that
the first Injectafer trial will start on June 5, 2023. (PDF).
The plaintiffs must file their pre-trial memoranda by May
22, 2023, while the defendants must do the same by May 29, 2023, according to
the court's ruling. Each of these contains a synopsis of the case, the contentions
of the parties, any agreements reached by the attorneys, a list of specific
admissions, a witness and exhibit list, and other significant case information.
Those who are filing Injectafer lawsuits can get the help of
LezDo
techmed for medical record reviews as they had aided their hand in the
recent mass tort litigations like roundup
lawsuit, Essure
lawsuits, CPAP
lawsuits, Zostavax
lawsuits and so on.
injectafer
class action lawsuit
injectafer class action lawsuit
Comments
Post a Comment